Article Information
History
- March 3, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Chih-Yun Laia,b,1,
- Albert Toa,1,
- Teri Ann S. Wonga,
- Michael M. Liebermana,
- David E. Clementsc,
- James T. Sendac,
- Aquena H. Balla,
- Laurent Pessaintd,
- Hanne Andersend,
- Oreola Doninie and
- Axel T. Lehrera,b,*
- aDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA
- bPacific Center for Emerging Infectious Disease Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA
- cHawaii Biotech, Inc., Honolulu, HI, USA
- dBioqual Inc., Rockville, MD, USA
- eSoligenix, Inc, Princetown, NJ, USA
- ↵*Corresponding author at: University of Hawaii at Manoa, John A. Burns School of Medicine, Department of Tropical Medicine, 651 Ilalo Street, Honolulu, HI 96813, United States (Axel T. Lehrer: lehrer{at}hawaii.edu)
↵1 These authors contributed equally to this work
Posted March 03, 2021.
Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice
